Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
P-Glycoprotein (ABCB1/MDR1) and BCRP (ABCG2) Limit Brain Accumulation and Cytochrome P450-3A (CYP3A) Restricts Oral Exposure of the RET Inhibitor Selpercatinib (RETEVMO).
Pharmaceuticals (Basel). 2021 Oct 27;14(11):1087. doi: 10.3390/ph14111087.
Pharmaceuticals (Basel). 2021.
PMID: 34832869
Free PMC article.
ABCB1 and ABCG2, but not CYP3A4 limit oral availability and brain accumulation of the RET inhibitor pralsetinib.
Wang Y, Sparidans RW, Potters S, Lebre MC, Beijnen JH, Schinkel AH.
Wang Y, et al. Among authors: potters s.
Pharmacol Res. 2021 Oct;172:105850. doi: 10.1016/j.phrs.2021.105850. Epub 2021 Aug 25.
Pharmacol Res. 2021.
PMID: 34450308
Item in Clipboard
Re-evaluation of putative rheumatoid arthritis susceptibility genes in the post-genome wide association study era and hypothesis of a key pathway underlying susceptibility.
Barton A, Thomson W, Ke X, Eyre S, Hinks A, Bowes J, Gibbons L, Plant D; Wellcome Trust Case Control Consortium; Wilson AG, Marinou I, Morgan A, Emery P; YEAR consortium; Steer S, Hocking L, Reid DM, Wordsworth P, Harrison P, Worthington J.
Barton A, et al.
Hum Mol Genet. 2008 Aug 1;17(15):2274-9. doi: 10.1093/hmg/ddn128. Epub 2008 Apr 22.
Hum Mol Genet. 2008.
PMID: 18434327
Free PMC article.
Item in Clipboard
Cite
Cite